PDS 0102
Alternative Names: PDS-0102; Versamune®-TARPLatest Information Update: 28 Jul 2025
At a glance
- Originator PDS Biotechnology Corporation
- Developer National Cancer Institute (USA); PDS Biotechnology Corporation
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Breast cancer; Prostate cancer
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (SC, Injection)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Breast-cancer in USA (SC, Injection)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Prostate-cancer in USA (SC, Injection)